Financial Performance - The company's revenue for Q1 2025 was CNY 187,242,875.58, representing a 5.16% increase compared to CNY 178,058,819.17 in the same period last year[4] - Net profit attributable to shareholders decreased by 3.17% to CNY 17,109,527.99 from CNY 17,670,252.56 year-on-year[4] - The company's basic earnings per share decreased by 4.17% to CNY 0.23 from CNY 0.24 year-on-year[4] - Net profit for the current period was ¥17,007,426.37, slightly down from ¥17,638,311.26 in the previous period, representing a decrease of 3.6%[19] - Earnings per share (EPS) for the current period was ¥0.23, compared to ¥0.24 in the previous period[20] Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 4,224,156.30, a 382.43% increase from a negative cash flow of CNY -1,495,654.65 in the previous year[4] - Cash inflow from operating activities totaled ¥133,278,454.70, significantly higher than ¥92,707,705.87 in the previous period, marking an increase of 43.7%[22] - The net cash flow from operating activities was 4,224,156.30, a significant improvement from the previous period's negative cash flow of -1,495,654.65[23] - Cash inflow from investment activities reached 958,147,125.93, up from 580,638,710.89 in the previous period[23] - The net cash flow from investment activities was -56,833,082.45, a decline from the previous period's positive cash flow of 58,471,234.40[23] - Cash inflow from financing activities amounted to 136,296,628.05, compared to 101,116,615.87 in the prior period[23] - The net cash flow from financing activities increased to 61,959,260.62 from 3,810,123.30 in the previous period[23] Assets and Liabilities - Total assets increased by 1.29% to CNY 2,011,100,312.28 compared to CNY 1,985,396,036.66 at the end of the previous year[4] - Total current assets increased to CNY 1,086,819,116.31 from CNY 1,063,088,386.12, reflecting a growth of approximately 2.3%[15] - Total liabilities decreased from CNY 521,263,307.26 to CNY 497,432,448.74, a reduction of approximately 4.5%[15] - Total liabilities increased to ¥669,113,027.68 from ¥661,718,705.69, showing a growth of 1.9%[16] - Total equity attributable to shareholders of the parent company rose to ¥1,341,025,065.38 from ¥1,322,613,010.13, an increase of 1.4%[16] Research and Development - The company reported a significant increase in research and development expenses, which rose by 74.34% to CNY 763.60 from CNY 437.99 in the same period last year[9] - Research and development expenses rose to ¥7,635,984.13, up 74.5% from ¥4,379,916.17 in the previous period, indicating a strong focus on innovation[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,501[11] Financial Management - The company experienced a 67.23% increase in trading financial assets, amounting to CNY 45,201.59, due to cash management using idle raised funds[8] - Trading financial assets significantly increased to CNY 452,015,943.14 from CNY 270,295,332.05, representing a growth of approximately 67.2%[14] - Financial expenses increased to ¥3,504,779.31, compared to ¥1,394,119.37 in the previous period, reflecting higher interest costs[19]
广康生化(300804) - 2025 Q1 - 季度财报